Telix Pharmaceuticals Ltd
ASX:TLX
Telix Pharmaceuticals Ltd
ASX:TLX
Price:
14.97 AUD
-0.53%
Market Closed
Updated:
May 7, 2024
Income Statement
Earnings Waterfall
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
|
Revenue
|
502.5m
AUD
|
|
Cost of Revenue
|
-188.2m
AUD
|
|
Gross Profit
|
314.4m
AUD
|
|
Operating Expenses
|
-296.8m
AUD
|
|
Operating Income
|
17.6m
AUD
|
|
Other Expenses
|
-12.4m
AUD
|
|
Net Income
|
5.2m
AUD
|
Income Statement
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Currency: AUD
| Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue |
3
N/A
|
5
+59%
|
7
+25%
|
8
+17%
|
29
+278%
|
160
+457%
|
357
+123%
|
503
+41%
|
|
| Gross Profit | |||||||||
| Cost of Revenue |
(3)
|
(2)
|
(2)
|
(3)
|
(12)
|
(65)
|
(134)
|
(188)
|
|
| Gross Profit |
1
N/A
|
3
+487%
|
5
+42%
|
5
+11%
|
16
+227%
|
95
+476%
|
223
+134%
|
314
+41%
|
|
| Operating Income | |||||||||
| Operating Expenses |
(32)
|
(39)
|
(56)
|
(82)
|
(133)
|
(186)
|
(249)
|
(297)
|
|
| Selling, General & Administrative |
(19)
|
(24)
|
(32)
|
(47)
|
(79)
|
(87)
|
(178)
|
(134)
|
|
| Research & Development |
(22)
|
(23)
|
(28)
|
(34)
|
(45)
|
(81)
|
(87)
|
(129)
|
|
| Depreciation & Amortization |
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
0
|
|
| Other Operating Expenses |
12
|
14
|
9
|
4
|
(3)
|
(12)
|
21
|
(34)
|
|
| Operating Income |
(32)
N/A
|
(36)
-12%
|
(52)
-45%
|
(77)
-49%
|
(116)
-51%
|
(91)
+22%
|
(27)
+71%
|
18
N/A
|
|
| Pre-Tax Income | |||||||||
| Interest Income Expense |
(7)
|
(11)
|
(6)
|
2
|
3
|
(1)
|
(5)
|
(1)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
|
| Total Other Income |
(0)
|
(1)
|
(3)
|
(5)
|
(6)
|
(6)
|
(9)
|
(13)
|
|
| Pre-Tax Income |
(39)
N/A
|
(48)
-24%
|
(61)
-28%
|
(80)
-32%
|
(119)
-48%
|
(99)
+17%
|
(40)
+59%
|
3
N/A
|
|
| Net Income | |||||||||
| Tax Provision |
3
|
3
|
2
|
(0)
|
(0)
|
(5)
|
(7)
|
2
|
|
| Income from Continuing Operations |
(36)
|
(45)
|
(59)
|
(81)
|
(119)
|
(104)
|
(48)
|
5
|
|
| Net Income (Common) |
(36)
N/A
|
(45)
-25%
|
(59)
-32%
|
(81)
-36%
|
(119)
-48%
|
(104)
+12%
|
(48)
+54%
|
5
N/A
|
|
| EPS (Diluted) |
-0.14
N/A
|
-0.17
-21%
|
-0.22
-29%
|
-0.29
-32%
|
-0.4
-38%
|
-0.34
+15%
|
-0.15
+56%
|
0.02
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
